Tag Archives: NASDAQ:STML

Cantor Fitzgerald Keeps a Buy Rating on Stemline Therapeutics (STML)

In a report issued on March 27, Alethia Young from Cantor Fitzgerald reiterated a Buy rating on Stemline Therapeutics (STML – Research Report), with a price target of $10.00. The company’s shares closed last Monday at $4.40, close to its

H.C. Wainwright Reiterates Their Buy Rating on Stemline Therapeutics (STML)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Stemline Therapeutics (STML – Research Report), with a price target of $18.00. The company’s shares closed last Monday at $4.06, close to its 52-week low

What Did This CEO Just Do with Personal Shares of Stemline Therapeutics (NASDAQ: STML)?

Yesterday, the CEO of Stemline Therapeutics (STML – Research Report), Ivan Bergstein, sold shares of STML for $286.2K. In addition to Ivan Bergstein, 6 other STML executives reported Sell trades in the last month. See today’s analyst top recommended stocks

H.C. Wainwright Sticks to Their Buy Rating for Stemline Therapeutics (STML)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Stemline Therapeutics (STML – Research Report) today and set a price target of $20.00. The company’s shares closed last Monday at $6.18, close to its 52-week low of $5.57. According

The CAO of Stemline Therapeutics (NASDAQ: STML) is Selling Shares

Yesterday, the CAO of Stemline Therapeutics (STML – Research Report), David Gionco, sold shares of STML for $48.96K. In addition to David Gionco, 5 other STML executives reported Sell trades in the last month. See today’s analyst top recommended stocks

The COO of Stemline Therapeutics (NASDAQ: STML) is Selling Shares

Yesterday, the COO of Stemline Therapeutics (STML – Research Report), Kenneth Hoberman, sold shares of STML for $502K. In addition to Kenneth Hoberman, 5 other STML executives reported Sell trades in the last month. See today’s analyst top recommended stocks